N@N

BioDelivery Sciences to Host Analyst & Investor Day June 3rd in New York City

^{Published on 2010-05-26 05:30:59 - Market Wire}
 

RALEIGH, N.C.--([ BUSINESS WIRE ])--BioDelivery Sciences International, Inc. (Nasdaq:BDSI) today announced that the Company will host an Analyst & Investor Day on Thursday, June 3, 2010 from 11:00 AM to 1:00 PM Eastern Time at the Intercontinental New York Barclay hotel in New York City.

Dr. Mark A. Sirgo, President and Chief Executive Officer and Dr. Andrew L. Finn, Executive Vice President of Product Development will host the session. Global experts in pain management and the treatment of opioid dependence with first-hand experience in clinical studies of, as well as prescribing, ONSOLIS (fentanyl buccal soluble film) and buprenorphine will provide insight into the profile and benefits of both drugs. In addition, BDSI will review the status of the clinical development programs and commercial opportunity for BEMA Buprenorphine in pain and opioid dependence.

The event will be webcast live and can be accessed at [ www.bdsi.com ]. For those who are not available to listen to the live broadcast, the presentation will be archived. Those interested in attending the event should contact Lena Adams at [ lena.adams@icrinc.com ] or Michael Leone at [ michael.leone@icrinc.com ].

About BioDelivery Sciences International

BioDelivery Sciences (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care. BDSIa™s pain franchise consists of two products utilizing BDSIa™s patented BEMA buccal soluble film technology. ONSOLIS (fentanyl buccal soluble film) was approved by FDA in July 2009 for the management of breakthrough pain in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The commercial rights to ONSOLIS are licensed to Meda who launched ONSOLIS in the U.S. last October. BDSIa™s second pain product in development, BEMA Buprenorphine, just completed Phase 2 clinical development for the treatment of chronic pain, and entering Phase1 as a higher dose formulation for the treatment of opioid dependence. Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron) and migraine (BEMA aTriptana). BDSIa™s headquarters is located in Raleigh, North Carolina.

BDSI^® and BEMA^® are registered trademarks of BioDelivery Sciences International, Inc. ONSOLIS^® is a registered trademark of Meda Pharmaceuticals, Inc.

Cautionary Note on Forward-Looking Statements

This press release and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the aCompanya) related thereto including any statements made at the presentations referred to herein, contain, or may contain, among other things, certain aforward-looking statementsa within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties, many of which are beyond the Companya™s control. Such statements may include, without limitation, statements with respect to the Companya™s plans, objectives, projections, expectations and intentions and other statements identified by words such as aprojects,a amay,a acould,a awould,a ashould,a abelieves,a aexpects,a aanticipates,a aestimates,a aintends,a aplans,a or similar expressions. These statements are based upon the current beliefs and expectations of the Companya™s management and are subject to significant risks and uncertainties, including those detailed in the Companya™s filings with the Securities and Exchange Commission. Actual results may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.